Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Colour key	
	Minimum requirements as set out in Directive 2004/23/EC
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Non-reproductive tissues and cells

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
VIRAL									
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	N/A	all	all		NO	
	Anti-HIV 2	YES	NO	N/A	all	all			
	HIV 1p24								
	HIV NAT	YES	NO	N/A	deceased, living (only allogeneic donors)	all	All deceased donors need to be tested by serological test AND viral NAT-tests (HIV, HBV, HCV). All living donors (allogenic grafts) need to be tested by serological tests AND viral NAT-tests (no quarantine) or 180-day-test (quarantine). Living donors (autologous grafts) need to be tested by serological tests.		
	Ag HIV								
	Other technique								
Hepatitis B	HBs Ag	YES	NO	N/A	all	all		NO	
	Anti-HBc	YES	NO	N/A	all	all			
	Anti - HBs								
	HBV NAT	YES	NO	N/A	deceased, living (only allogeneic donors)	all	All deceased donors need to be tested by serological test AND viral NAT-tests (HIV, HBV, HCV). All living donors (allogenic grafts) need to be tested by serological tests AND viral NAT-tests (no quarantine) or 180-day-test (quarantine). Living donors (autologic grafts) need to be tested by serological tests.		
	Other technique								
Hepatitis C	Anti-HCV	YES	NO	N/A	all	all		NO	
	HCV NAT	YES	NO	N/A	deceased, living (only allogeneic donors)		All deceased donors need to be tested by serological test AND viral NAT-tests (HIV, HBV, HCV). All living donors (allogenic grafts) need to be tested by serological tests AND viral NAT-tests (no quarantine) or 180-day-test (quarantine). Living donors (autologic grafts) need to be tested by serological tests.		
	Other technique								

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
HTLV-1	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-HTLV-1	YES	NO	N/A	donors living in or originating from a high prevalence area, or parents or sexual partners originating from those areas	all			
	HTLV-1 NAT								
	Other technique								
HTLV-2	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-HTLV-1								
	HTLV-2 NAT								
	Other technique								
Chikungunya virus									
Cytomegalovirus	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-CMV								
	CMV NAT								
	Other technique								
Dengue Virus									
Ebola Virus									
Epstein-Barr virus	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-EBV								
	Other technique								
Hepatitis E									
Human Parvovirus B19									
Herpes simplex virus									
West Nile Virus									
specify pathogen									
PARASITIC									
Babesiosis									
Leishmaniasis									
Malaria	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Microscopy								
	Plasmodium sp . Ab								
	Plasmodium sp . Ag								
	Plasmodium sp. Ag - rapid test								
	Plasmodium sp. NAT								
	Other technique								
Toxoplasmosis	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-*Toxoplasma gondii*								

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
	Microscopy								
	Other technique								
Trypanosomiasis	Technique not specified	YES	NO	N/A	risk groups	all		NO	
	Anti-*Trypanosoma cruzi*								
	Microscopy								
	Other technique								
specify pathogen									
BACTERIAL									
Treponema pallidum (Syphilis)	Technique not specified	YES	NO	N/A	all	all	According to the directive: A validated testing algorithm must be applied to exclude the presence of active infection with Treponema pallidum. A non-reactive test, specific or non-specific, can allow tissues and cells to be released. When a non-specific test is performed, a reactive result will not prevent procurement or release if a specific Treponema confirmatory test is non-reactive. A donor whose specimen tests reactive on a Treponema-specific test will require a thorough risk assessment to determine eligibility for clinical use.	NO	
	Anti-*T. pallidum*								
	Microscopy								
	T. pallidum NAT								
	Other technique								
Chlamydia trachomatis									
Neisseria gonorrhoeae									
Brucellosis									
Tuberculosis									
Q-fever									
specify pathogen									
FUNGI									
specify pathogen									
Transmissible spongiform encephalopathies									
Other Tests									
ABO blood group testing									
RhD blood group testing	RhD typing	YES	NO	N/A	risk groups	all		NO	
	Other technique								
HLA testing	Technique not specified	YES	NO	N/A	risk groups	all		NO	

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
	HLA Ab								
	HLA Ag								
	HLA gene								
	Other technique								
Genetic testing, please specify condition									

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Colour key	
	Minimum requirements as set out in Directive 2004/23/EC
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Reproductive tissues and cells

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
VIRAL									
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	N/A	all except IUI (partner donation, direct use)	all		NO	No testing is required in the case of partner donation of reproductive cells for direct use - IUI.
	Anti-HIV 2	YES	NO	N/A	all except IUI (partner donation, direct use)	all			
	HIV 1p24								
	HIV NAT	YES	NO	N/A	sperm donor (non-partner donation) **	sperm	All deceased donors need to be tested by serological test AND viral NAT-tests (HIV, HBV, HCV). All living donors (allogenic grafts) need to be tested by serological tests AND viral NAT-tests (no quarantine) or 180-day-test (quarantine). Living donors (autologous grafts) need to be tested by serological tests.		
	Ag HIV								
	Other technique								
Hepatitis B	HBs Ag	YES	NO	N/A	all except IUI (partner donation, direct use)	all		NO	
	Anti-HBc	YES	NO	N/A	all except IUI (partner donation, direct use)	all			
	Anti - HBs								
	HBV NAT	YES	NO	N/A	sperm donors (non-partner donation) **	sperm	**) NAT OR 180-day-re-testing required		
	Other technique								
Hepatitis C	Anti-HCV	YES	NO	N/A	all except IUI (partner donation, direct use)	all		NO	
	HCV NAT	YES	NO	N/A	sperm donor (non-partner donation) **	sperm	**) NAT OR 180-day-re-testing required		
	Other technique								
HTLV-1	Technique not specified	NO	NO	N/A	risk groups	all		NO	
	Anti-HTLV-1	YES	NO	N/A	donors living in or originating from a high prevalence area, or parents or sexual partners originating from those areas	all			

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
	HTLV-1 NAT								
	Other technique								
HTLV-2									
Chikungunya virus									
Cytomegalovirus									
Dengue Virus									
Ebola Virus									
Epstein-Barr virus									
Hepatitis E									
Human Parvovirus B19									
Herpes simplex virus									
West Nile Virus									
specify pathogen									
PARASITIC									
Babesiosis									
Leishmaniasis									
Malaria									
Toxoplasmosis									
Trypanosomiasis									
specify pathogen									
BACTERIAL									
Treponema pallidum (Syphilis)	Technique not specified	YES	NO	N/A	non-partner donors	all		NO	
	Anti-*T. pallidum*								
	Microscopy								
	T. pallidum NAT								
	Other technique								
Chlamydia trachomatis	Technique not specified							NO	
	C. trachomatis DFA								
	C. trachomatis EIA								
	C. trachomatis NAT	NO	NO	N/A	sperm donors (non-partner donation)	sperm			
	Culture								
	Other technique								
Neisseria gonorrhoeae									
Brucellosis									
Tuberculosis									
Q-fever									
specify pathogen									
FUNGI									
specify pathogen									
Transmissible spongiform encephalopathies									
Other Tests									
ABO blood group testing									
RhD blood group testing									

Finland - More stringent blood donor testing requirements
2015 Mapping exercise

Tested pathogen	Donor test/ technique	Legally binding	Recommended on national level	Recommending authority/ association	Circumstances for application			Regional differences	Further comments
					Donor profile	Tissue/cell type	Comments		
HLA testing									
Genetic testing, please specify condition									